Abstract

Over the last 20 yr, there has been extraordinary growth in the biopharmaceutical industry based on the development of recombinant DNA and hybridoma technologies in the 1970s. Prior to this, the dependence on extraction from natural sources severely limited the range and quantity of proteins available for clinical use. Recombinant DNA technology made it possible to mass produce a wide range of natural and modified proteins for the first time. In addition, hybridoma technology introduced a new class of protein reagents—the monoclonal antibodies (MAbs)—that provided an alternative approach to treat many diseases.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.